TIDMRMS

RNS Number : 6403M

Remote Monitored Systems PLC

22 January 2021

22 January 2021

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Remote Monitored Systems plc ("RMS" or the "Company")

EN14683 Certification Successful

Update on Commissioning

Remote Monitored Systems plc ("RMS" or the "Company") announces that further to the announcement on 18 January 2021, Pharm 2 Farm Ltd ("P2F") has today received the report from Eurofins confirming that the P2F mask has now been certified as meeting the EN14683 standard having passed the biocompatibility test. The EN14683 standard comes on top of the ISO18184 certificate announced in November 2020 and, once in production, the mask can now be sold in the UK and Europe as a viricidal Type IIR mask.

To achieve the EN14683 standard, the mask had to pass five tests, as follows:

Bacterial Filtration Efficiency (BFE): this tests the filtration capacity of the mask. The P2F product achieved a 98.77%; higher than the 98% required and close to the 99% needed for FFP3 respirator.

Differential Pressure: this tests the breathability of the mask. The maximum limit to obtain Type IIR is <60pa/cm(2) . The P2F mask achieved 46.4pa/cm(2) which provides a good balance of breathability and BFE.

Splash resistance: this tests the resistance of the mask to penetration by blood fluid at 16kPa. It is the only required for Type IIR (differentiating it from Type II) as this type of mask can be used in a surgical setting. The key to passing the test is to have a hydrophobic outer layer on the mask. 100% of the masks in P2F sample passed this test compared to the minimum 90% pass rate requirement.

Microbiological cleanliness: this measures the quantity of microorganisms on the mask, effectively, checking the cleanliness of the manufacturing environment. The P2F masks passed, coming in below the maximum permitted measure of 30 cfu/g (Note: CFU is a microbiological measure for the number of viable cells in a sample).

Biocompatibility test: this tests the reaction to human skin - cytotoxicity, irritation and sensitization. The tests which included a biological evaluation and in-vitro cytotoxicity were performed to evaluate the effects of limited (less than 24 hours) and cumulative prolonged use of the mask (from 24hrs to 30 days). The P2F mask performed very well against the controls in all cases and hence are considered to be not cytotoxic and not irritative.

Commissioning of the machine at BioCity, Nottingham, commenced this week but is taking longer than anticipated, as parts have been delayed in transport from Spain, and will extend into early next week, pushing back the start of production and reducing the number of masks that can be produced before the end of January.

The Company looks forward to providing further updates in due course.

Antony Legge, Chairman, said: "Achieving the EN14683 standard is a great step forward as this was a key factor for potential customers and the sales effort can now begin in earnest. The delay in commissioning, caused by customs and transport difficulties in Europe, has been very frustrating but it now should be just a matter of a few days to complete the work."

- ENDS -

ENQUIRIES :

Remote Monitored Systems plc

Antony Legge (Chairman) +44 7394 489177

Alex Vergopoulos (Executive Director)

SP Angel Corporate Finance LLP +44 20 3470 0470

Nominated Adviser and Joint Broker

Stuart Gledhill

Caroline Rowe

Peterhouse Capital Limited +44 20 7469 0930

Joint Broker

Lucy Williams

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSEFFEEEFSELF

(END) Dow Jones Newswires

January 22, 2021 07:56 ET (12:56 GMT)